Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis

Update Il y a 5 ans
Reference: NCT01085084

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules (0.5mg /day and 1mg /day) in active lupus arthritis patients. Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. For Multiple Sclerosis.


Inclusion criteria

  • Lupus Arthritis

Links